Category: Press Releases

• CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.
• CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales, with a favourable safety profile.
• CognivAiD has a unique ‘multimodal mechanism of action’, reinforcing Moleac’s dedication to developing scientifically proven innovative formulations for patients with neurological conditions.

SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) — Moleac announced on 29^th October 2022 the launch of CognivAiD, the first-in-market specific product for Vascular Dementia (VaD). An optimized formulation of active extracts from Gingko, Ginseng and Saffron, CognivAiD shows significant and clinically meaningful disease-modifying benefits in patients with VaD, a condition with no targeted treatment at present.

David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives. Over the past 20 years, we have built a unique platform to develop and bring to patients innovative medicines meeting their needs in neurology. This was done with our flagship product NeuroAiDII, which currently benefits patients from over 35 countries. Our strategy now is to leverage our expertise, infrastructure and partners to bring more therapies to those suffering from a loss of brain functions. We are very proud to launch CognivAiD which fills a big gap in the treatment of vascular dementia and the cognitive disorders it causes.”

More than 55 million people currently live with dementia globally, with an incidence of over 10 million cases every year. This presents a huge financial and economic burden, amounting to an annual global cost of US$1.3 trillion that is expected to rise to US$2.8 trillion by 2030¹. Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases².

The current treatment options for VaD include acetylcholinesterase inhibitors (AChE inhibitors) such as donepezil, and NMDA antagonists such as memantine. However, these options do not specifically target the key mechanisms of VaD.

“There are currently very few therapeutic options available for patients with VaD. The existing options are non-specific with modest documented benefits, and they may have undesirable side effects in this frail population. Thanks to years of research in the lab and in clinical trials, CognivAiD is now available as a new therapeutic option, slowing down the cognitive decline of VaD patients and helping them to maintain their daily living activities. It targets the complex disease pathways of VaD via its properties of vascular protection, vasoregulation, and modulation of neuroinflammation. Its efficacy and safety are well-established in rigorous clinical trials published in peer-reviewed journals. We are proud at Moleac to provide access to CognivAiD, a new safe and effective treatment that will benefit VaD patients and their caregivers,” said Dr. Sylvain Durrleman, Head of Medical Affairs at Moleac.

For more information, visit www.cognivaid.com.

About CognivAiD

CognivAiD is an evidence-based formulation comprising active extracts from Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma which has been shown to be safe and effective for the treatment of vascular dementia.

About Moleac

Moleac is a biopharmaceutical company committed to helping patients and families reconnect with their lives. Headquartered in Singapore, we are dedicated to developing scientifically proven innovative formulations that bridge therapeutic gaps and address unmet needs of patients with neurological conditions such as stroke, traumatic brain injuries and dementia.

Moleac’s flagship product NeuroAiDII reaches more than 30,000 patients in over 35 countries every year. CognivAiD, the company’s new product for vascular dementia, was launched in October 2022.

For more information, visit www.moleac.com.

Name of Press Contact: Clement Dif

Phone: +65 6211 3710

Email: communication@moleac.com

GlobeNewswire Distribution ID 8730125

---

• Call comes ahead of World Economic Forum annual meeting
• Schneider-commissioned research finds most companies planning to spend under 2% of revenues on sustainability and decarbonization initiatives
• On the demand side of the energy transition, only 31% of organizations currently push electrification as a way to decarbonize

Rueil-Malmaison (France), January 16, 2023 – Schneider Electric, the leader in the digital transformation of energy management and automation, today issued an urgent call for governments and companies around the world to accelerate their sustainability action and step up investments into technologies that will help them reduce their carbon emissions and bolster their energy security.

The call comes amid spiking energy prices, an energy supply crisis and fast accelerating climate change, which together pose major challenges for companies, economies and societies around the globe. These challenges form the backdrop for the World Economic Forum’s annual meeting in Davos, Switzerland, from 16-20 January, which senior Schneider Electric executives will attend.

“Today’s climate and energy crises are an economic reality for ever-increasing numbers of people. As business leaders and policymakers come together at Davos, we must act in our own best long-term, not short-term, interests,” said Jean-Pascal Tricoire, Schneider Electric’s Chairman and CEO.  “We must not avoid the tough decisions. There can be no long-term prosperity without a complete energy transition. At Schneider, our approach is to ‘Digitize Strategize, Decarbonize’ – businesses, governments and societies must do this now, to make good on the commitments they have made.“

With 38% of global CO₂ emissions coming from the built environment, and a further 32% from industry¹, Schneider Electric’s products, software and services in the areas of industrial automation and energy management help companies, industries, building managers and households to decarbonize and digitize their energy usage. Schneider Electric also offers deep insights into decarbonization trends and solutions, through surveys, research and in-depth reports compiled by the Schneider Electric Sustainability Research Institute.

An independent survey of more than 500 C-suite executives commissioned by Schneider last year  found that corporate sustainability commitments and investments are often hampered by the complexity of decarbonization. On average, the financial commitment to sustainability and decarbonization initiatives across the companies surveyed was less than 2% of projected revenue over the next three years – despite the fact such investments are often efficient and cost-effective, with return on investment often under one to three years.
Respondents highlighted stakeholder alignment, budget, technology, skills and regulation as challenges to sustainability implementation. However, a majority noted that enhanced industrial automation and the upgrading of electrical infrastructure will form a key part of their sustainability plan for the next three years.

Renewable energy procurement is among the top initiatives pursued on the supply side, while electrification – a key demand-side measure – scores low among organizations’ sustainability priorities. Alongside electrification, delivering increased efficiency across existing infrastructure through digitization and automation will be among the most important levers in the next decade, being the fastest and most capital-efficient means for many organizations to reduce emissions.

Embracing sustainability as a business imperative, with digital solutions key to navigating the global energy crisis

A further recent Schneider Electric report on the EU’s electrification potential found that focusing on sectors in which electrification is both feasible and attractive could raise electricity’s share of the energy mix from around 20% to 50%. In turn, the share of natural gas and oil would drop by around 50%, contributing significantly to improved energy security. Schneider Electric offers specific, practical solutions to help companies navigate this transition more quickly and efficiently.

Schneider Electric points out that today’s European energy crisis follows decades of secure, reliably available energy and relatively stable pricing. Many are experiencing for the first time unpredictable energy supplies and unaffordable prices, demonstrating a failure both of long-term energy security preparedness, and of the implementation of decarbonization plans. This in turn underscores the importance of reevaluating the entire energy equation, from the supply side (energy transition) to the demand side (energy efficiency).

“Purpose and profits must align to become powerful forces in the fight against climate change,” said Mr. Tricoire. “We already have the technology to avert the energy and climate crises, and to deliver safe, reliable, and sustainable energy distribution and energy use. Our data-driven approach, spanning industrial automation, digitization and the digital twin technology of the enterprise metaverse, combines to unlock a brighter, more sustainable and more prosperous future. The urgency for action has never been greater than it is now.”

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

¹ IEA Global Energy Review: CO2 Emissions, 2021

GlobeNewswire Distribution ID 1000777376

Amsterdam, 13 January 2023 – Today, Azerion has announced that it will simplify its reporting structure by merging the parent company Azerion Group N.V. and Azerion Holding B.V.. As a result, the surviving entity Azerion Group N.V. will publish one report with the interim unaudited results for the fourth quarter 2022 and one set of consolidated financial statements for the full year 2022.

Ben Davey, CFO of Azerion, commented: “As we build our track record as a listed company, we continue to focus on simplifying our operating structure and improving transparency. Merging our two main reporting entities is an important step in this process.”

The intention to affect this merger was announced on 28 October 2022 and the merger was completed on 31 December 2022.

Contact:
Investor Relations
ir@azerion.com

Media
press@azerion.com

DISCLAIMER

The companies in which Azerion Group N.V. directly and indirectly owns investments are separate legal entities. In this announcement “Azerion”, “Azerion Group” and “Group” are sometimes used for convenience where references are made to Azerion Group N.V. and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Azerion Group N.V. and its subsidiaries in general or to those who work for them.

This press release is for information purposes only. The information contained in this press release does not purport to be full or complete and, in particular, is not intended to form the basis of any investment decision. No reliance may be placed by any person for any purpose on the information contained in this press release or its accuracy, fairness or completeness. Azerion will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided.

This press release may include forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as believes, estimates, plans, projects, anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause the actual results of Azerion to differ materially from future results expressed or implied by such forward-looking statements. Any forward-looking statements reflect Azerion’s current views and assumptions based on information currently available to Azerion’s management. Forward-looking statements speak only as of the date they are made, and Azerion does not assume any obligation to update such statements, except as required by law. No assurances can be given that the forward-looking statements will be realised. No representation or warranty is made that any of these forward-looking statements will come to pass or that any estimated result will be achieved. Accordingly, no undue reliance should be placed on any forward-looking statements.

GlobeNewswire Distribution ID 1000777073

Spiralling Growth in Consumer Demand for Natural Alternative Therapies Driving Healthcare Professionals to Spend More Time Learning Online

ORLANDO, Fla., Jan. 12, 2023 (GLOBE NEWSWIRE) — Niel Asher Education is pleased to announce that three dynamic new faculty members will join NAT Global Campus in spring 2023. The addition of these leading experts and innovators in the fields of Manual Medicine and Traditional Chinese Medicine further demonstrates its commitment to providing its student community with the highest standards of education online.

Dr. Constance Bradley, L.Ac., Ph.D., will present NAT courses on acupuncture and TCM. Dr. Bradley attended the US Air Force Academy, receiving a Bachelor of Science in Humanities in 2001. In 2002, she graduated from the University of Colorado, receiving a Master of Arts in Philosophy with an emphasis in Medical Ethics. In 2009 she received her Doctorate from the University of Utah.

“Niel Asher leads the way in providing top-notch continuing education, and I am honored to join their team. I look forward to sharing my Traditional Chinese Medicine expertise, and I am very excited to work with Niel Asher to create high-quality, informative courses,” she said.

Dr. Linda Bluestein, MD, is a Board-certified anesthesiologist, integrative pain medicine physician and former ballet dancer, who specializes in treating dancers and other athletes at increased risk of hyper-mobility and connective tissue disorders such as EDS.

Dr. Bluestein completed her anesthesiology residency at the Mayo Graduate School of Medicine after receiving her Medical Degree from the University of California, Los Angeles School of Medicine and is a member of the International Association for Dance Medicine and Science, the Performing Arts Medicine Association, and the Resources Committee for the Dance Healthy Alliance of Canada.

“I am thrilled to work with Niel Asher Education to create courses on symptomatic joint hypermobility.  It is exciting to work with them on educational offerings about these frequently misunderstood and complex conditions,” she said.

Dr. Elizabeth Wagner, Ph.D., earned her Doctorate in Physical Therapy from the University of Washington. She has also earned a certificate of competency in vestibular rehabilitation and is certified in Mechanical Diagnosis and Therapy.

“I am thrilled to collaborate with NAT to create high-quality continuing education courses. I look forward to contributing my 15 years of experience as a physical therapist and teacher to NAT’s ongoing efforts of supporting this vibrant community,” she said.

The NAT Global Campus has grown to become one of the largest online schools for Natural Alternative Therapies in manual medicine and serves over 100,000 students in over 40 countries.

NAT Global Campus’ Director Dani P. Marks stated, “Our most significant health challenges continually demand fresh takes and multidisciplinary approaches. This group of outstanding new faculty is joining a team of specialist teachers committed to deliver on this promise, and to help provide our students with the skills and knowledge to improve outcomes and provide outstanding care in their communities.”

Contact Information:
Dani Marks
Interim Director, NAT Global Campus
dani@nielasher.com
8147771964

Related Images

Image 1: Niel Asher Education

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Niel Asher Education

GlobeNewswire Distribution ID 8729025

CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) — Amlan^® International, the animal health business of Oil-Dri^® Corporation of America, is pleased to announce its participation in the International Production and Processing Expo (IPPE) January 24-26, 2023, in Atlanta, GA. Attendees will learn more about the latest in feed technology for animal protein producers that optimize gut health through three exciting TECHTalks, a new product showcase featuring Phylox^®, and two poster presentations during the International Poultry Scientific Forum (IPSF). Amlan is also proud to be the exclusive sponsor of the IPPE Media Center. Amlan looks forward to welcoming a global audience of animal production professionals and sharing more about its range of products with attendees, media and other exhibitors at its booth, B5453.

Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets). Phylox is a research-backed, natural alternative to anticoccidial drugs that supports gut health naturally thus improving productivity and, in turn, driving producers’ profits. This year, Phylox will be highlighted during the expo’s new product showcase. Attendees can watch a video presentation to learn more about the company’s latest innovation.

“We look forward to speaking with producers about how Phylox, a bioactive blend of antiprotozoal phytochemicals with multiple modes of action, decreases the negative production and health effects of coccidiosis,” said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri, and President, Amlan International. “Phylox is natural and can be used in “no antibiotics ever” (NAE) programs, has no withdrawal requirements, and can be fed in combination with anticoccidial vaccines preventing disease breakthrough.”

“We are excited about the success of our North American portfolio, which includes Sorbiam and Enterotec. The industry reaction to these products created to optimize animal gut health has been tremendous,” according to Heath Wessels, Vice President of Sales, The Americas. “Working with our key customers, our products continue to demonstrate the efficacy of our mineral-based feed additives.”

Attendees can learn more about the latest in protein and feed technology presented during TECHTalks.

On Tuesday, January 24:

• Dr. Marc Herpfer, VP, New Technologies, Oil-Dri Corporation of America, will present “Natural Mineral Technology as an Alternative to AGPs” in B Hall, Booth B8675 at 11:00 a.m.
• Dr. Josh Payne, Dir. Technical Service, Poultry Guard, will present “Best Management Practices and Utilization of Clay-Based Litter Amendment for pH and Ammonia Control” in B Hall, Booth B3646 at 11:30 a.m.

On Wednesday, January 25:

• Mike Donohue, VP, Agri Stats, Inc. will present “The Importance of 1%, The Effect of Efficiency on Sustainability and Economic Value” in B Hall, Booth B3646 at 10:00 a.m.

“TECHTalks are an excellent way for us to provide valuable information on specific technical challenges the industry is facing,” says Dr. Aldo Rossi, Vice President, Innovation and Technical Service. “We are proud of our high-quality and efficacious mineral-based feed additives for poultry and livestock, and how they can improve the quality of animal protein. We look forward to sharing our solutions with producers.”

During the International Poultry Scientific Forum (IPSF) on January 23, Amlan experts will present two posters, selected by IPSF, detailing research designed to support optimal poultry intestinal health and bring the latest production technology to producers. The presentations will be from 4:00 p.m. to 6:00 p.m.:

• Feeding Varium^® produces growth performance similar to feeding an antibiotic on-farm, by Dr. Sara (LeAnn) Johnston, Technical Service Manager, Amlan International
• A natural coccidiostat, Phylox Feed, improves performance, intestinal lesion scores, and fecal oocyst shedding of Eimeria-infected broilers, Dr. San (Chris) Ching, Senior Research Manager, Amlan International.

Amlan is continuing to proudly celebrate its 15^th anniversary of providing natural mineral-based feed additives to the industry. The Amlan brand was introduced into the feed-additive market in 2007. Vertical integration allows Amlan to leverage Oil-Dri’s mineral science expertise to develop novel, natural feed additives. Oil-Dri launched its first mineral-based product, an industrial floor absorbent, in 1941, and since then has mined and processed a range of unique minerals for many applications. Oil-Dri has been active in the animal health market since the 1980s, with products that assist feed flowability and pellet binding.

“As the proud exclusive sponsor of the IPPE Media Center, Amlan looks forward to building relationships with media from around the world,” says Reagan Culbertson, Vice President of Strategic Marketing, B2B. “We hope media professionals will visit the Media Center to work, network and visit with our experts about Amlan’s unique and exciting mineral technology.”

For more information on Amlan International, please visit: www.amlan.com

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process its unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

GlobeNewswire Distribution ID 8729202